- Home
- FMY vs KLRS Comparison
FMY vs KLRS Comparison
Compare FMY & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMY
- KLRS
- Stock Information
- Founded
- FMY 2005
- KLRS 2019
- Country
- FMY United States
- KLRS United States
- Employees
- FMY N/A
- KLRS N/A
- Industry
- FMY Finance/Investors Services
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FMY Finance
- KLRS Health Care
- Exchange
- FMY Nasdaq
- KLRS Nasdaq
- Market Cap
- FMY 51.6M
- KLRS 46.0M
- IPO Year
- FMY N/A
- KLRS N/A
- Fundamental
- Price
- FMY $12.00
- KLRS $4.97
- Analyst Decision
- FMY
- KLRS Strong Buy
- Analyst Count
- FMY 0
- KLRS 2
- Target Price
- FMY N/A
- KLRS $23.00
- AVG Volume (30 Days)
- FMY 10.1K
- KLRS 175.7K
- Earning Date
- FMY 01-01-0001
- KLRS 11-15-2025
- Dividend Yield
- FMY 6.98%
- KLRS N/A
- EPS Growth
- FMY N/A
- KLRS N/A
- EPS
- FMY N/A
- KLRS N/A
- Revenue
- FMY N/A
- KLRS N/A
- Revenue This Year
- FMY N/A
- KLRS N/A
- Revenue Next Year
- FMY N/A
- KLRS N/A
- P/E Ratio
- FMY N/A
- KLRS N/A
- Revenue Growth
- FMY N/A
- KLRS N/A
- 52 Week Low
- FMY $10.71
- KLRS $2.14
- 52 Week High
- FMY $12.17
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- FMY 37.01
- KLRS 49.92
- Support Level
- FMY $11.96
- KLRS $4.70
- Resistance Level
- FMY $12.16
- KLRS $5.30
- Average True Range (ATR)
- FMY 0.09
- KLRS 0.41
- MACD
- FMY -0.02
- KLRS -0.06
- Stochastic Oscillator
- FMY 11.11
- KLRS 67.48
About FMY First Trust Motgage Income Fund of Beneficial Interest
First Trust Mortgage Income Fund is a United States based diversified, closed-end management investment company. The fund's primary investment objective is to seek a high level of current income. Its secondary investment objective is to preserve capital. The fund pursues its objectives by investing predominantly in mortgage-backed securities representing part ownership in a pool of either residential or commercial mortgage loans that, in the opinion of the Fund's investment advisor, offer an attractive combination of credit quality, yield and maturity.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.